The Neuro news
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS. Three studies conducted by an international team of researchers, which included Amit Bar-Or and Douglas Arnold from the Montreal Neurological Institute and Hospital of McGill University, have discovered that ocrelizumab can significantly reduce new attacks in patients with relapsing MS, as well as slow the progression of symptoms caused by primary progressive MS.
November 19 marks the 50th anniversary of the ground-breaking paper, “Pain Mechanisms: A New Theory” co-authored by McGill’s Ronald Melzack, and the late Patrick Wall, which introduced gate-control theory.
The Montreal Neurological Institute and Hospital – The Neuro at McGill University and the MUHC has Canada’s oldest MS clinic but is always innovating - striving for progress and better treatments for patients. What’s new in MS at The Neuro
Four innovative projects led by McGill University researchers have been selected to receive major grants under the Canada Brain Research Fund.
As part of The Neuro’s Thinking Ahead Campaign, a $240,000 donation from Desjardins Group, the largest financial cooperative group in Canada, to The Montreal Neurological Institute and Hospital – The Neuro, McGill University has enabled the creation of the Desjardins Outstanding Student Award. Twelve awards of 20 000 $ each will support top-rated graduate students and postdoctoral fellows who are advancing research to better understand the nervous system and neurological disorders and aid in developing new therapies.